This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

Clinical Trial Overview

Last Updated: 11/19/2026

SUMMARY

  • Data on pharmacokinetics (PK), safety, tolerability, and efficacy of milvexian are available from phase 1 and phase 2 clinical trials. Phase 3 trials are currently in progress.
  • For completed as well as ongoing clinical trials of milvexian, see Table: Clinical Trials Evaluating Milvexian.

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.


Clinical Trials Evaluating Milvexian
Phase
Trial
Description
Status
Phase 3
Librexia AF
NCT05757869
N=20,000
Aged ≥18 years
Multicenter, randomized, double-blind, doubledummy, active-controlled, parallelgroup study evaluating the efficacy and safety of milvexian 100 mg BID vs apixaban 5 mg or 2.5 mg BID in participants with AF1
Ongoing
Librexia ACS
NCT05754957
N=16,000
Aged ≥18 years
Multicenter, randomized, double-blind, placebocontrolled, parallel-group, eventdriven study evaluating the efficacy and safety of milvexian 25 mg BID in participants after a recent (within 7 days) ACS2. (On November 14, 2025, Johnson & Johnson in collaboration with Bristol Myers Squibb announced the decision to stop the Phase 3 Librexia ACS trial. Please click here for the link to the press release.3)
Discontinued
Librexia STROKE
NCT05702034


N=15,000
Aged ≥40 years
Multicenter, randomized, double-blind, placebocontrolled, parallel-group study evaluating the efficacy and safety of milvexian 25 mg BID for the prevention of recurrent ischemic stroke after an AIS or high-risk TIA4
Ongoing
Phase 2
AXIOMATIC-TKR
NCT03891524


N=1242
Aged ≥50 years
Multicenter, open-label, randomized, drug-dose blind study evaluating the efficacy and safety of milvexian vs SC enoxaparin in participants undergoing elective TKR surgery5,6
Completed
AXIOMATIC-SSP
NCT03766581


N=2366
Aged ≥40 years
Multicenter, randomized, double-blind, placebocontrolled, dose-ranging study of milvexian for the prevention of new ischemic stroke or new covert brain infarction in participants receiving aspirin and clopidogrel following AIS or TIA7,8
Completed
Phase 1/2
A study to evaluate safety of single doses of BMS986177 in patients with ESRD treated with hemodialysis
NCT03000673
N=32
Aged 1875 years
Open-label, randomized, crossover study assessing the safety and tolerability of single oral doses of milvexian in participants with ESRD treated with chronic hemodialysis9
Completed
Phase 1
Safety and tolerability study of BMS-986177 in healthy subjects
NCT02608970
N=104
Aged 18- 55 years
Two-part, randomized, double-blind, placebocontrolled, sequential SAD and MAD study evaluating the safety, tolerability, and PK of single and multiple doses of milvexian in healthy participants10,11
Completed
Evaluate the pharmacokinetics of BMS-986177 from 2 formulations in healthy participants
NCT03362437
N=12
Aged 1855 years
Open-label, randomized study evaluating the PK of milvexian from 2 formulations (capsule and suspension) in healthy participants12,13
Completed
A study of JNJ70033093 (milvexian) in healthy adult participants
NCT04844424
N=115
Aged 1855 years
Open-label, randomized, crossover study assessing the relative oral bioavailability, PK, and food effect after single-dose or multipledose administration of milvexian in healthy participants using tablet, capsule, and dispersed tablet formulations14
Completed
A study of JNJ70033093 in healthy participants
NCT04448964
N=24
Aged 18-55 years
Open-label, randomized, 3-way crossover and 2-way crossover study evaluating the relative bioavailability and the food effect of an oral tablet formulation relative to a capsule formulation of milvexian in healthy participants15
Completed
A study of JNJ70033093 (BMS986177) in healthy adult participants
NCT04223349
N=66
Aged 1855 years
Open-label, single-dose crossover, double-blind, multiple-dose, parallel-group study characterizing the PK, safety, and tolerability and PD of milvexian in healthy adult participants16
Completed
A study of milvexian using an IV microtracer with additional formulation and food effect comparison in healthy participants
NCT04965389
N=17
Aged 1865 years
Open-label, randomized, crossover study assessing the absolute oral bioavailability of milvexian using a 14C-microtracer and oral solution in healthy participants with additional food effect comparison of a spray-dried dispersion formulation of milvexian in capsules17
Completed
A study to evaluate the safety and pharmacokinetics of BMS-986177 in participants with ESRD on chronic stable hemodialysis treatment
NCT02902679
N=6
Aged ≥18 years
Open-label study evaluating the safety and PK of milvexian in participants with ESRD on chronic stable hemodialysis treatment18
Completed
Evaluate pharmacokinetics and safety of BMS986177 in participants with normal renal function and with moderate or severe renal impairment
NCT03196206
N=24
Aged 1870 years
Open-label, parallel-group study evaluating the PK, safety, and tolerability of a single dose of milvexian in participants with normal renal function and with moderate or severe renal impairment19,20
Completed
Single-dose pharmacokinetics of BMS-986177 in participants with hepatic impairment compared to healthy participants
NCT02982707
N=26
Aged 1870 years
Open-label, parallel-group, non-randomized study evaluating the PK, safety, and tolerability of a single oral dose of milvexian 60 mg in participants with normal hepatic function (n=9), mild hepatic impairment (Child-Pugh class A; n=9), and moderate hepatic impairment (ChildPugh class B; n=8)21,22
Completed
Pharmacokinetic and metabolism of [14C] BMS-986177 in healthy male participants
NCT03939702
N=9
Aged 1850 years
Open-label, non-randomized study assessing the ADME of [14C] milvexian in healthy male participants23,24
Completed
To evaluate the safety and pharmacokinetics of BMS-986177 in healthy Japanese participants
NCT03224260
N=33
Aged 1855 years
Randomized, double-blind, placebo-controlled, MAD study assessing the safety and tolerability of milvexian in healthy Japanese participants25,26
Completed
A study of JNJ70033093 (BMS986177) in healthy Chinese adult participants
Phase 1
NCT04569695
N=40
Aged 1855 years
Randomized, open-label, parallel-group, single and multiple-dose study characterizing the PK, PD, and safety and tolerability of milvexian in healthy Chinese participants27
Completed
A study to evaluate the effect of coadministration of itraconazole or diltiazem on the pharmacokinetics of BMS-986177 in healthy subjects
NCT02807909
N=28
Aged 1855 years
Open-label, non-randomized trial evaluating the effects of itraconazole and diltiazem on the PK and PD of milvexian in healthy participants28,29
Completed
A study to evaluate the effect of rifampin on the single-dose pharmacokinetics of BMS-986177 in healthy subjects
NCT02959060
N=16
Aged 1855 years
Open-label, non-randomized, single-sequence study evaluating the effect of rifampin on the PK and PD of milvexian in normal healthy participants30,31
Completed
An investigational study to assess the effect of BMS-986177 on aspirin in healthy participants
NCT03341390
N=20
Aged 1855 years
Double-blind, randomized, placebo-controlled, parallel-group study evaluating the effect of coadministration of multiple doses of milvexian on aspirin in healthy participants32
Completed
A study to assess administration of an oral anti-thrombotic with antiplatelet therapy in healthy subjects
NCT03698513
N=113
Aged 1855 years
Randomized, crossover study evaluating the safety, tolerability, PK, and PD of milvexian with single and dual antiplatelet therapy (aspirin and clopidogrel) in healthy participants33-35
Completed
A study of JNJ70033093 and digoxin in healthy participants
NCT04206488
N=30
Aged 1855 years
Single-center, open-label, fixed-sequence study assessing the 2-way drug-drug interaction between milvexian and digoxin in healthy participants36
Completed
A study evaluating drug-drug interaction between milvexian and atorvastatin in healthy participants
Phase 1
NCT04388501
N=23
Aged 1855 years
Single-center, open-label, randomized, 3way crossover study assessing drug-drug interaction between milvexian and atorvastatin in healthy participants37
Completed
A study to assess the reversal of the anticoagulant effects of milvexian by 4FPCC) (part 1) and rFVIIa (part 2) in healthy participants
NCT04543383
N=46
Aged 1854 years
Two-part, open-label, randomized, placebocontrolled, crossover study evaluating the reversal of the anticoagulant effects of milvexian by 4F-PCC and rFVIIa in healthy participants38
Ongoing
A study of milvexian in healthy adult females
NCT05706753
N=20
Aged 1855 years
Open-label, non-randomized study assessing the effects of milvexian BID administration on the PK of single doses of midazolam, ethinylestradiol, and drospirenone in healthy adult female participants39
Ongoing
Abbreviations: 4F-PCC, 4-factor prothrombin complex concentrate; ACS, acute coronary syndrome; ADME, absorption, distribution, metabolism, and excretion; AIS, acute ischemic stroke; AF, atrial fibrillation; BID, twice daily; ESRD, end-stage renal disease; IV, intravenous; MAD, multiple ascending dose; PD, pharmacodynamics; PK, pharmacokinetics; rFVIIa, recombinant human factor VIIa; SAD, single ascending dose; SC, subcutaneous; TIA, transient ischemic attack; TKR, total knee replacement.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 04 February 2026.

References

1 Janssen Research & Development, LLC. A study of milvexian versus apixaban in participants with atrial fibrillation (LIBREXIA-AF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT05757869 NLM Identifier: NCT05757869.  
2 Janssen Research & Development, LLC. A study of milvexian in participants after a recent acute coronary syndrome (LIBREXIA-ACS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT05754957 NLM Identifier: NCT05754957.  
3 Update on Phase 3 Librexia ACS Trial. Press Release. Bristol Myers Squibb.  Available at: https://news.bms.com/news/corporate-financial/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx Bristol Myers Squibb; Accessed Accessed 04 Febraury 2026.  
4 Janssen Research & Development, LLC. A study of milvexian in participants after an acute ischemic stroke or high-risk transient ischemic attack - LIBREXIA-STROKE (LIBREXIA-STROK). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05702034 NLM Identifier: NCT05702034.  
5 Janssen Research & Development, LLC. A study of JNJ-70033093 (BMS-986177) versus subcutaneous enoxaparin in participants undergoing elective total knee replacement surgery (AXIOMATIC-TKR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03891524 NLM Identifier: NCT03891524.  
6 Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161-2172.  
7 Bristol-Myers Squibb. A study on BMS-986177 for the prevention of a stroke in patients receiving aspirin and clopidogrel (AXIOMATIC-SSP). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03766581 NLM Identifier: NCT03766581.  
8 Sharma M, Molina CA, Toyoda K, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46-59.  
9 Bristol-Myers Squibb. A study to evaluate safety of single doses of BMS-986177 in patients with end stage renal disease (ESRD) treated with hemodialysis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03000673 NLM Identifier: NCT03000673.  
10 Bristol-Myers Squibb. Safety and tolerability study of BMS-986177 in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02608970 NLM Identifier: NCT02608970.  
11 Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330-342.  
12 Bristol-Myers Squibb. Evaluate the pharmacokinetics of BMS-986177 from two formulations in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03362437 NLM Identifier: NCT03362437.  
13 Perera V, Wang Z, Good D, et al. Relative bioavailability of spray-dried dispersion suspension or spray-dried dispersion granule capsule of milvexian (BMS-986177/JNJ-70033093), an oral, direct, reversible, small molecule factor XIa inhibitor. Poster presented at: the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; March 8-12 and 15-17, 2021; Virtual.  
14 Janssen Research & Development, LLC. A study of JNJ-70033093 (milvexian) in healthy adult participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04844424 NLM Identifier: NCT04844424.  
15 Janssen Research & Development, LLC. A study of JNJ-70033093 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04448964 NLM Identifier: NCT04448964.  
16 Janssen Research & Development, LLC. A study of JNJ-70033093 (BMS-986177) in healthy adult participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04223349 NLM Identifier: NCT04223349.  
17 Bristol-Myers Squibb. A study of milvexian using an IV microtracer with additional formulation and food effect comparison in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04965389 NLM Identifier: NCT04965389.  
18 Bristol-Myers Squibb. A study to evaluate the safety and pharmacokinetics of BMS-986177 in participants with end-stage renal dysfunction on chronic stable hemodialysis treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02902679 NLM Identifier: NCT02902679.  
19 Bristol-Myers Squibb. Evaluate pharmacokinetics and safety of BMS-986177 in participants with normal renal function and with moderate or severe renal impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03196206 NLM Identifier: NCT03196206.  
20 Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment. Clin Pharmacokinet. 2022;61(10):1405-1416.  
21 Bristol-Myers Squibb. Single-dose pharmacokinetics of BMS-986177 in participants with hepatic impairment compared to healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02982707 NLM Identifier: NCT02982707.  
22 Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022;61(6):857-867.  
23 Bristol-Myers Squibb. Pharmacokinetic and metabolism of [14^C] BMS-986177 in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03939702 NLM Identifier: NCT03939702.  
24 Abelian G, Christopher L, Iyer R, et al. Pharmacokinetics and mass balance of [14C] milvexian in healthy male participants. Poster presented at: the American College of Clinical Pharmacology (ACCP) Annual Meeting; September 25-17, 2022; North Bethesda, Maryland, US.  
25 Bristol-Myers Squibb. To evaluate the safety and pharmacokinetics of BMS-986177 in healthy Japanese participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03224260 NLM Identifier: NCT03224260.  
26 Perera V, Wang Z, Lubin S, et al. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Sci Rep. 2022;12(1):5165.  
27 Janssen Research & Development, LLC. A study of JNJ-70033093 (BMS-986177) in healthy chinese adult participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04569695 NLM Identifier: NCT04569695.  
28 Bristol-Myers Squibb. A study to evaluate the effect of co-administration of itraconazole or diltiazem on the pharmacokinetics of BMS-986177 in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02807909 NLM Identifier: NCT02807909.  
29 Perera V, Wang Z, Lubin S, et al. Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor. Cardiol Ther. 2022;11(3):407-419.  
30 Bristol-Myers Squibb. A study to evaluate the effect of rifampin on the single-dose pharmacokinetics of BMS-986177 in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02959060 NLM Identifier: NCT02959060.  
31 Perera V, Wang Z, Lubin S, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Sci Rep. 2022;12(1):22239.  
32 Bristol-Myers Squibb. An investigational study to assess the effect of BMS-986177 on aspirin in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03341390 NLM Identifier: NCT03341390.  
33 Bristol-Myers Squibb. A study to assess administration of an oral anti-thrombotic with antiplatelet therapy in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT03698513 NLM Identifier: NCT03698513.  
34 Perera V, Abelian G, Luettgen J, et al. A randomized crossover study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants. Poster presented at: the European Society of Cardiology (ESC) Congress; August 26-29, 2022; Barcelona, ES and Virtual.  
35 Perera V, Abelian G, Luettgen J, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants. Sci Rep. 2024;14(1):16591.  
36 Van Hoogdalem M, Steinbach D, Ajavon-Hartmann A, et al. A single-center, open-label, fixed-sequence study evaluating the two-way drug-drug interaction between milvexian & digoxinin healthy subjects. Abstract presented at: Annual Meeting American College of Clinical Pharmacology, CPDD 2025; 2025-9-1; Phoenix,AZ United States.  
37 D. S, Ajavon-Hartmann A, Zannikos P, et al. A single-center, open-label, randomized, three-way cross-over study evaluating drug-drug interaction between milvexian & atorvastatin in healthy participants. Abstract presented at: Annual Meeting American College of Clinical Pharmacology, CPDD 2025; 2025-9-1; Phoenix,AZ United States.  
38 Janssen Research & Development, LLC. A study to assess the reversal of the anticoagulant effects of milvexian by 4-factor prothrombin complex concentrate (4F-PCC) and recombinant human factor VIIa (rFVIIa) (Part 2) in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT04543383 NLM Identifier: NCT04543383.  
39 Janssen Pharmaceutica N.V., Belgium. A study of milvexian in healthy adult females. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT05706753 NLM Identifier: NCT05706753.  

Would you like to clear and leave your conversation? Message history will be lost.